
A friend rang me after her father's cardiology appointment. He's 79, has atrial fibrillation, takes an anticoagulant, and has had two frightening bleeds. The consultant had mentioned "a device" — a small plug placed in the heart that might let him come off the blood thinner. Was it a good idea?
I didn't know. So I read the two trials that came out this year — and they disagree. Which turns out to be the most useful thing about them.
What the trials found
First, the idea. In atrial fibrillation, the heart's upper chambers quiver instead of pumping cleanly, and blood can pool in a little pouch called the left atrial appendage. Clots that form there can travel to the brain. Anticoagulants — "blood thinners" — prevent that, at the cost of bleeding more easily. Left atrial appendage closure takes a different route: a catheter threads a small device into the pouch and seals it, so the clot has nowhere to form. In principle, you then need less anticoagulation, or none.
Trial one: CLOSURE-AF (Landmesser et al., New England Journal of Medicine, 2026). Run in Germany and funded by the German Centre for Cardiovascular Research — public money — it recruited people very much like my friend's father: 912 adults, average age 78, with atrial fibrillation and a high risk of both stroke and bleeding. Half had the device fitted; half received "physician-directed best medical care", which meant whatever their doctor judged best, including modern anticoagulants if they could take them.
The researchers counted a composite of stroke, clots elsewhere in the body, major bleeding, and death from cardiovascular or unexplained causes, and asked whether the device was at least not worse than medical care. After a median of three years, those events had happened at a rate of 16.8 per 100 patient-years in the device group and 13.3 in the medical group. The device failed to prove it was not inferior. Serious adverse events were also more common with the device: 82.5% of patients versus 77.4%.
Trial two: CHAMPION-AF (Doshi et al., New England Journal of Medicine, 2026). This one was funded by Boston Scientific, which makes the device, and it recruited a different crowd: 3,000 people, average age 72, who were suitable for anticoagulation — not the high-bleeding-risk group. They were randomised to the device or to a modern anticoagulant tablet.
Here the device held up. At three years, the composite of cardiovascular death, stroke or systemic embolism had occurred in 5.7% of the device group and 4.8% of the anticoagulant group — close enough to count as "non-inferior" by the trial's pre-set rules. And bleeding not related to the procedure itself was almost halved: 10.9% against 19.0%.
Why the two trials disagree
Not because one is right and one is wrong. Because they asked different questions of different people.
Different patients. CLOSURE-AF chose the sickest group — older, high stroke risk, high bleeding risk — exactly the people the device was invented for. CHAMPION-AF chose people who could take anticoagulants comfortably.
Different comparisons. In CLOSURE-AF the device was up against tailored medical care, chosen by a doctor who knew the patient. In CHAMPION-AF it was up against one standard anticoagulant.
Different scorekeeping. CLOSURE-AF put major bleeding inside its main outcome — the thing the device is supposed to prevent — and the device still didn't win. CHAMPION-AF kept bleeding separate, where the device shone, while the main outcome excluded it.
And a note on "non-inferior". CHAMPION-AF allowed the device to be worse by up to 4.8 percentage points and still pass — a generous margin when the comparison group's event rate was itself 4.8%. The device group did have slightly more strokes, deaths and embolisms (5.7% versus 4.8%). Non-inferior is not the same as better; it means "not worse by more than we agreed to tolerate".
What's still uncertain
Both trials are three-year snapshots of a lifelong condition. CHAMPION-AF is still ongoing. Neither abstract tells us how many people in the device arms ended up back on anticoagulants anyway, which is the detail my friend's father would most want to know.
And the device isn't a once-and-done fix in the way a tablet is not: it's a procedure, with procedural risks, performed by operators whose experience varies.
What you can do
If you or a parent is offered left atrial appendage closure, the most useful question isn't "does it work?" — it's "which of these two trials looks like me?" If the answer is "older, bleeding often, struggling on anticoagulants", be aware that the public trial in exactly that group did not find the device better than careful medical care. If the answer is "I take my anticoagulant fine but hate the bleeding risk", the picture is more encouraging — with the caveats above.
Either way, never stop an anticoagulant on your own. Ask your doctor to walk you through where you sit between these two trials, and what the plan for anticoagulation would be after any procedure. The NHS atrial fibrillation treatment page lists medicines, cardioversion and ablation; the device isn't among the standard options there, which tells you it's a selective choice, not a default.
Two trials, two answers, and the honest summary is: it depends on who you are. That's not a cop-out. It's what good evidence looks like when it's new.
Curiosity first.
— Dr. Brugal
Related on Dr. Brugal
For the procedures that have arrived in cardiology lately, read The cardiology procedures your cardiologist may not have had five years ago. If you help a parent with a long medicine list — anticoagulants included — see The system that works when there are more than four medications. And on the heart after 60, Fasting after 60: what it means for your heart.
References
All studies retrieved via PubMed.
- Landmesser U, Skurk C, Kirchhof P, et al. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. New England Journal of Medicine. 2026;394(13):1270-1280. Multicentre randomised non-inferiority trial in people, 912 patients with atrial fibrillation at high risk of stroke and bleeding, median follow-up 3 years. doi:10.1056/NEJMoa2513310 (PMID 41849741)
- Doshi SK, Kar S, Nair DG, et al. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. New England Journal of Medicine. 2026;394(21):2083-2094. International randomised non-inferiority trial in people, 3,000 patients with atrial fibrillation suitable for anticoagulation, 3 years. doi:10.1056/NEJMoa2517213 (PMID 41910347)
Awareness content — not medical advice. Always talk to your doctor or pharmacist before making changes.